X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with Fresenius Kabi Onco. - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs FRESENIUS KABI ONCO. - Comparison Results

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB FRESENIUS KABI ONCO. UNICHEM LAB/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 29.1 22.1 131.7% View Chart
P/BV x 3.1 3.1 98.6% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 UNICHEM LAB   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    UNICHEM LAB
Mar-16
FRESENIUS KABI ONCO.
Mar-13
UNICHEM LAB/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs334176 189.8%   
Low Rs17479 221.7%   
Sales per share (Unadj.) Rs146.937.7 389.8%  
Earnings per share (Unadj.) Rs11.95.1 233.5%  
Cash flow per share (Unadj.) Rs16.26.7 240.8%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs105.142.5 247.1%  
Shares outstanding (eoy) m90.84158.23 57.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x1.73.4 51.2%   
Avg P/E ratio x21.425.0 85.5%  
P/CF ratio (eoy) x15.718.9 82.9%  
Price / Book Value ratio x2.43.0 80.8%  
Dividend payout %16.80-   
Avg Mkt Cap Rs m23,07320,135 114.6%   
No. of employees `0005.71.2 492.4%   
Total wages/salary Rs m2,558703 363.8%   
Avg. sales/employee Rs Th2,352.55,176.2 45.4%   
Avg. wages/employee Rs Th450.9610.4 73.9%   
Avg. net profit/employee Rs Th190.4699.6 27.2%   
INCOME DATA
Net Sales Rs m13,3465,963 223.8%  
Other income Rs m19218 1,066.1%   
Total revenues Rs m13,5385,981 226.3%   
Gross profit Rs m1,6391,430 114.6%  
Depreciation Rs m390258 151.2%   
Interest Rs m29-26 -110.8%   
Profit before tax Rs m1,4121,216 116.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m-40-   
Extraordinary Inc (Exp) Rs m-35-68 51.8%   
Tax Rs m293342 85.5%   
Profit after tax Rs m1,080806 134.1%  
Gross profit margin %12.324.0 51.2%  
Effective tax rate %20.728.1 73.7%   
Net profit margin %8.113.5 59.9%  
BALANCE SHEET DATA
Current assets Rs m5,9795,102 117.2%   
Current liabilities Rs m2,4322,385 102.0%   
Net working cap to sales %26.645.6 58.4%  
Current ratio x2.52.1 115.0%  
Inventory Days Days63150 42.0%  
Debtors Days Days60113 53.3%  
Net fixed assets Rs m6,4035,148 124.4%   
Share capital Rs m182158 114.9%   
"Free" reserves Rs m9,2936,556 141.8%   
Net worth Rs m9,5486,732 141.8%   
Long term debt Rs m230952 24.2%   
Total assets Rs m12,84310,388 123.6%  
Interest coverage x50.0-45.8 -109.3%   
Debt to equity ratio x00.1 17.1%  
Sales to assets ratio x1.00.6 181.0%   
Return on assets %8.67.5 115.0%  
Return on equity %11.312.0 94.5%  
Return on capital %14.314.6 98.2%  
Exports to sales %29.274.5 39.2%   
Imports to sales %6.324.8 25.6%   
Exports (fob) Rs m3,9004,441 87.8%   
Imports (cif) Rs m8471,477 57.3%   
Fx inflow Rs m4,3565,298 82.2%   
Fx outflow Rs m1,1621,772 65.6%   
Net fx Rs m3,1943,525 90.6%   
CASH FLOW
From Operations Rs m1,1191,274 87.8%  
From Investments Rs m-853-1,204 70.9%  
From Financial Activity Rs m-334-196 170.4%  
Net Cashflow Rs m-68-126 54.1%  

Share Holding

Indian Promoters % 50.1 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 15.1 0.3 5,033.3%  
FIIs % 3.0 9.6 31.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 9.1 348.4%  
Shareholders   20,176 42,599 47.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   AJANTA PHARMA  GLENMARK PHARMA  SUN PHARMA  STRIDES SHASUN LTD  FDC LTD.  

Compare UNICHEM LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes Firm; Software & FMCG Stocks Gain(Closing)

Indian share markets finished the trading session well above the dotted line, snapping a three-day falling streak amid firm Asian markets.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Feb 21, 2018 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB 8-QTR ANALYSIS

COMPARE UNICHEM LAB WITH

MARKET STATS